Rumblings and worries about Obama's FDA options

As Obama solidifies his teams on science, education, and environment, attention -- and not a little worry from the drug industry -- is turning toward his hunt for a new FDA commissioner. The WSJ Health Blog reports that the FDA Commissioner Coalition, which is heavy with groups financed by the drug industry, appears increasingly concerned that Obama will appoint outspoken critics of drugmakers and the FDA, such as Cleveland Clinic cardiologist Steven Nissen or Baltimore health commissioner Joshua Sharfstein, who is heading Obama's FDA assessment team.

While the coalition prominently talks about the need for an FDA chief who can withstand some kinds of outside pressure, there’s no mention of an ability to withstand pressure from industry. Yet undue industry influence is at the heart of concerns from both parties in both houses of Congress, from FDA officials, from doctors and many medical researchers.

A copy of the Coalition's letter (to Secretary of Health Designate Tom Daschle) can be found at Pharmalot.

Categories

More like this

This post by Science's Jennifer Couzin at ScienceInsider suggests how much serious overhaul the FDA needs. Looks like some scientists at the Food and Drug Administration are doing what they can to influence president elect Obama's choice of their new boss. Nine scientists have written to Obama's…
President Obama used his weekly radio address last weekend to talk about an urgent matter for all Americans. Which one? It could have been any of a half dozen, but it was one that received essentially no attention from the last administration: food safety. He also officially announced his…
First, some welcome breaking news from Amie Newman at RH Reality Check: President Obama has rescinded the Global Gag Rule, which banned giving federal funds to internal groups that provide abortions or informations about the procedure. Jacob Goldstein at WSJ's Health Blog is also on top of the…
by Susan F. Wood  After the recent post here on KETEK, both the Wall Street Journal and Senator Grassley are on the move.  The WSJ reports today on another antibiotic Cubicin which has been seeking approval for use in endocarditis and discusses the competing issues of data quality and high…